Key Performance Forecast Data The company forecasts significant H1 2025 performance growth, with net profit attributable to shareholders increasing by approximately 72% and non-recurring net profit by 120% H1 2025 Performance Forecast vs. Prior Period | Metric | H1 2025 Estimate | Prior Period (H1 2024) | Year-on-Year Change | Year-on-Year Growth | | :--- | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Approx. 123.50 million CNY | 71.9844 million CNY | Approx. increase of 51.52 million CNY | Approx. 72% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | Approx. 119.40 million CNY | 54.3498 million CNY | Approx. increase of 65.05 million CNY | Approx. 120% | Prior Period Performance Review The company's H1 2024 financial results, including net profit attributable to shareholders, non-recurring net profit, and EPS, serve as the baseline for current performance comparisons H1 2024 Key Financial Data | Metric | H1 2024 Amount | | :--- | :--- | | Total Profit | 150.0084 million CNY | | Net Profit Attributable to Parent Company Shareholders | 71.9844 million CNY | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-recurring Items) | 54.3498 million CNY | | Earnings Per Share | 0.042 CNY | Performance Growth Drivers The company attributes its performance growth to optimized internal management, including enhanced budget control, lean management, and cost reduction initiatives - The company attributes performance growth to improved internal management efficiency, with specific measures including: - Deepening comprehensive budget control - Implementing lean management - Comprehensive quality and efficiency improvement - Reducing procurement costs and various expenses6 Risk Warning and Disclaimer The company advises that the performance forecast is a preliminary, unaudited estimate, with final figures subject to the official 2025 semi-annual report, urging investors to consider investment risks - This performance forecast is a preliminary calculation based on the professional judgment of the company's finance department and has not been audited by an accounting firm7 - The company confirms that as of the announcement date, there are no significant uncertainties affecting the accuracy of this performance forecast7 - The final accurate financial data will be disclosed in the company's official 2025 semi-annual report, reminding investors to be aware of risks8
华北制药(600812) - 2025 Q2 - 季度业绩预告